Article
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Antimicrobial agents and chemotherapy - 1 Sept 2007
Hazen Richard, Harvey Robert, Ferris Robert, Craig Charles, Yates Phillip, Griffin Philip, Miller John, Kaldor Istvan, Ray John, Samano Vincente, Furfine Eric, Spaltenstein Andrew, Hale Michael, Tung Roger, St Clair Marty, Hanlon Mary, Boone Lawrence
Abstract excerpt
Brecanavir, a novel tyrosyl-based arylsulfonamide, high-affinity, human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI), has been evaluated for anti-HIV activity in several in vitro assays. Preclinical assessment of brecanavir indicated that this compound potently inhibited HIV-1 in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.